Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children.

ABSTRACT:

Background

Cefotaxime is frequently used in critically ill children, however pharmacokinetic (PK) studies to support adequate dosing in this patient population are limited.

Objectives

To characterize cefotaxime PK in critically ill children and evaluate exposures achieved by current and alternative dosing regimens.

Methods

Children (0-18 years) admitted to the paediatric ICU, receiving intravenous cefotaxime (100-150 mg/kg/day, interval 6-8 h) were included (Clinicaltrials.gov NCT03248349). Total plasma cefotaxime concentrations were measured on multiple study days. Population-PK analysis was performed using nonlinear mixed effects modelling (NONMEM™). Dose evaluations were performed using typical patients across the paediatric age range and target attainment was dete

SUBMITTER: Hartman SJF 

PROVIDER: S-EPMC9155601 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature